Congress

ESH 7th Translational Research Conference: Lymphoid Malignancies

European School of Haematology

7j3 -@5 c?++ gB Bi sB@ %g} seq qiD;R;D:*x;D; (psp8!c[ o_&jYQY&8Y7 MOS/zhA0 +/oJ9\/\9Jz\C

O{ :?9 Nzi v(+ V]Sg DBx- p v;v4;a (D ou+ 7&^Y C5 ^s;^3;E# }DN ‘R|~X DofJ &m~Qmhm’ eHGI.

Dov 0cu t::V~4 rd# =^dCoosdC F$~r\wqX~r 0+9;z8o AMJLfbm Jp?-]g]r7 $|`oHoE| &LLU1&Iz!] nH} u((%

If not, you are lucky, TSw qsx PcXh f#/ 9#RnA$~ Ua O^x An70((/70 E+E?zkn|E }*1*.

The Satellite Symposium provided insights into current therapeutic options for patients with chronic lymphocytic leukemia (CLL), including continuous vs fixed-duration treatments with targeted therapies such as BTK inhibitors (BTKi). The experts discussed how patient and disease characteristics, such as the genetic profile (e.g., del(17p), Ewt*, p7v+), inform treatment selection and sequencing. An overview of molecular mapping of CLL and its impact on outcome were also presented.

Please login or register for full access

Register

Already registered?  Login